AZD4512
/ AstraZeneca
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 18, 2025
Lumi-NHL: A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
(clinicaltrials.gov)
- P1/2 | N=91 | Not yet recruiting | Sponsor: AstraZeneca
Monotherapy • New P1/2 trial • B Cell Non-Hodgkin Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology
1 to 1
Of
1
Go to page
1